In patients presenting with reflux symptoms and no esophagitis, this is the only goal. Prokinetics drugs bethanechol, metoclopramide, domperidone and cisapride have been shown to produce greater relief of symptoms compared to placebo in controlled studies [ 2 ]. Clinically, they are efficacious, but only in mild to moderate reflux disease. All are equally effective when used at proper dosages, usually with a twice a day dosing regimen.
Higher dosages of H 2 -blockers marginally improve on these results in patients with more severe symptoms.
However, I believe the drug of choice in these latter patients are the proton pump inhibitors. Unlike the H 2 -blockers where partial symptom relief is the rule, omeprazole usually totally relieves all symptoms allowing the patients to enjoy many previously prohibited foods and sleep without head elevation.
To obtain this goal, some patients may require higher doses of omeprazole in the range of 40 to 80 mg per day. Long-term symptom relief is more problematic. Patients with mild symptoms will remain in remission with H 2 -blockers or cisapride, usually given b. Those with severe symptomatic disease will require omeprazole or antireflux surgery.
Healing of esophagitis Today most cases of acute reflux esophagitis can be healed. However, this frequently requires marked acid suppression for a prolonged period of time. The key to treating and healing reflux esophagitis is the initial esophagitis grade. The more severe the grade of esophagitis, the stronger the acid suppression and the longer the duration of therapy required to heal the mucosal lesions. Antacids, alginic acids and most prokinetics drugs have no predicable reliability in healing even mild esophagitis [ 1 , 2 ].
Data with cisapride is more equivocal. European studies show healing of even severe esophagitis after 12 weeks of therapy, while studies in the United States show minimal efficacy primarily in grade II esophagitis [ 2 ]. Use precise geolocation data. Select personalised content. Create a personalised content profile. Measure ad performance. Select basic ads.
Create a personalised ads profile. Select personalised ads. Apply market research to generate audience insights. Measure content performance. Develop and improve products. List of Partners vendors. Erosive esophagitis is a type of esophagitis in which there is esophageal damage. Esophagitis is inflammation, irritation, or swelling of the lining of the esophagus, which is the tube that runs from the throat to the stomach. Studies indicate that the most common symptoms of esophagitis are heartburn, chest pain, and dysphagia discomfort swallowing.
Who qualifies for this research study? Men ages with Low Testosterone hypogonadism at an increased risk or history of Cardiovascular Disease. The clinical site will be able to provide more information about additional requirements for study participation.
Where are the research sites? There are approximately centers in the United States that are helping to conduct this study. When will I know if I qualify for a study? How long will my participation in the study last, if I qualify? Symptom relief does not rule out the existence of other serious stomach conditions. Patients are considered to be at risk if they are 60 and over, or if they have a history of previous stomach ulcer.
The meeting showcases approximately 5, abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. About AstraZeneca AstraZeneca is a major international healthcare business engaged in the research, development, manufacture, and marketing of prescription pharmaceuticals and the supply of healthcare services. For more information about AstraZeneca, please visit: www.
0コメント